Biostem Technologies (BSEM) Stock Price, News & Analysis

Company Overview

BioStem Technologies, Inc. (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.

Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair. BioStem emphasizes the processing and preservation of donated biologic tissues for use in clinical settings.

The company is based in Florida and serves the U.S. health-care market through relationships with medical providers, distributors and other health-care organizations. BioStem Technologies is led by Chief Executive Officer Jason Matuszewski. Additional information about the company’s historical operations and geographic reach is limited, and product availability and indications may vary by applicable regulatory requirements.

Key Stats

• Today's Range: $4.17 to $4.45
• 50-Day Range: $3.00 to $4.31
• 52-Week Range: $2.25 to $8.40
• Volume: 142,954 shs
• Average Volume: 101,893 shs
• Market Capitalization: $76.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Biostem Technologies Stock Analysis - MarketRank™

Biostem Technologies scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biostem Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Biostem Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biostem Technologies are expected to grow in the coming year, from ($1.90) to ($1.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biostem Technologies is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of Biostem Technologies has been sold short.

Short Interest Ratio / Days to Cover

Biostem Technologies has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biostem Technologies has recently decreased by 78.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biostem Technologies does not currently pay a dividend.

Dividend Growth

Biostem Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.72

News Sentiment

Biostem Technologies has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Biostem Technologies this week, compared to 4 articles on an average week.

Search Interest

39 people have searched for BSEM on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biostem Technologies insiders have not sold or bought any company stock.

Percentage Held by Institutions

Biostem Technologies has minimal institutional ownership at this time.

Company Calendar

• Today: 9/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BSEM
• CIK: 1658678
• Web: N/A
• Phone: (954) 380-8342
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $47.48 million
• Price / Sales: 1.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,850,000
• Free Float: N/A
• Market Cap: $76.93 million
• Optionable: N/A
• Beta: 0.12